CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 54 enrolled
Drug / intervention
Riluzole 50 mg orodispersible film +1 moredrug
Likely dose
Riluzole 50 mg orodispersible filmfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04819438
NCT04819438Phase 1Completed

Comparative Bioavailability Study of a New Riluzole Orodispersible Film vs. a Marketed Oral Reference (Rilutek® Tablets) in Healthy Male and Female Volunteers

Cross Research S.A.·interventional·Posted Mar 29, 2021·Updated May 2, 2025

In Brief

A Phase 1 clinical trial evaluating Riluzole 50 mg orodispersible film and Rilutek® 50 mg riluzole tablets for Healthy Participants. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The objective of the study is to compare the pharmacokinetic profile of riluzole after replicate single dose of the novel orodispersible film test formulation and of the marketed reference Rilutek® tablets and to evaluate their bioequivalence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSwitzerland
CollaboratorsZambon SpA

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedMar 29, 2021
Enrollment StartJan 15, 2021
Primary CompletionMar 14, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.3 years ago

Interventions

Riluzole 50 mg orodispersible filmdrug

Before each administration, the subjects will drink 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy will take the orodispersible film (32.0x22.0 mm) out of the provided pouch and place the product directly on the top surface (dorsal aspect) of the subjects' tongue.

Rilutek® 50 mg riluzole tabletsdrug

One film-coated tablet will be swallowed (without chewing) with 150 mL of still mineral water.